The Consortium for Applied Microbial Metrics develops new molecular pharmacodynamic markers that will accelerate pre-clinical drug development and human trials for tuberculosis and other bacterial diseases. Consortium investigators collaborate on complementary methods development and in vitro, animal and human studies. These projects apply novel pathogen RNA analysis methods to elucidate the impact of drugs and regimens on the physiologic state of bacterial populations. As a platform for cross-disciplinary collaborative innovation, the Consortium is developing practical new solutions to accelerate drug and regimen development for tuberculosis and other bacterial diseases.
For questions about the consortium please send emails to: